Camurus’ Oclaiz NDA resubmission accepted by FDA
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Subscribe To Our Newsletter & Stay Updated